Gene therapy and virotherapy: novel therapeutic approaches for brain tumors

KURT M KROEGER; AKM GHULAM MUHAMMAD; GJ BAKER; HIKMAT ASSI; MIA WIBOWO; WEIDONG XIONG; KADER YAGIZ; MARIANELA CANDOLFI; PEDRO R LOWENSTEIN; MARIA G CASTRO

DISCOVERY MEDICINE

Discovery Medicine

Año: 2010 p. 293 - 304

1539-6509

Glioblastoma multiforme (GBM) is a deadly primary brain tumor in adults, with a median survival of ~12-18 months post-diagnosis. Despite recent advances in conventional therapeutic approaches, only modest improvements in median survival have been achieved; GBM usually recurs within 12 months post-resection, with poor prognosis. Thus, novel therapeutic strategies to target and kill GBM cells are desperately needed. Our group and others are pursuing virotherapy and gene therapy strategies for the treatment of GBM. In this review, we will discuss various virotherapy and gene therapy approaches for GBM currently under pre-clinical and clinical evaluation including direct or conditional cytotoxic, and/or immunostimulatory approaches. We also discuss cutting-edge technologies for drug/gene delivery and targeting brain tumors, including the use of stem cells as delivery platforms, the use of targeted immunotoxins, and the therapeutic potential of using GBM microvesicles to deliver therapeutic siRNAs or virotherapies. Finally, various animal models available to test novel GBM therapies are discussed.